Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Dave who wrote (25297)	11/18/2006 12:47:25 AM
From: Paul Senior	Read Replies (1) \| Respond to of 78580

I never have been able to figure out what I should do about OID. It's either too expensive for me to subscribe to or else maybe I should look at it as it's too expensive for me NOT to subscribe to and avail myself of the often terrific interviews and stock suggestions. Couple years back - the last time I looked at OID closely - the subject of the issue was Japanese stocks - obscure ones where they only traded on Japanese market. Not stocks I could/would be able to get info. on or buy at reasonable commissions through my broker. For people who aren't familiar with Outstanding Investor Digest, here's a link to the current table of contents: oid.com Nice interview with Arnold Van Den Berg. I liked reading how he approaches the market and stocks. OTOH, there weren't any great insights - that I got anyway - about his particular stock picks. KO, WMT, others have been discussed here; I own some shares and am not likely to up position based on what I read in the article. Back otoh though, it's comforting to see somebody of Mr. Van Den Berg's stature recommending these stocks now. OID is published only when the owner feels like it. Subscriptions are for issues, not time periods. Looks like ten issues for $295. (That ten could be over a couple/three/four years.) Here's a link to the stocks mentioned in the current issue: oid.com Again, for me,... conflicting. I've previously reviewed almost all the companies on the list, and I either have established positions or passed on the stocks. (Indian company Ranbaxy is new to me. And too obscure to me.) So unless there were some compelling reason (not previously known to me) from the interviewed person for buying any of his/her picks now, the value to me is in the hand-holding of the stocks mentioned that I already have.